This is educational information, not medical advice, and The Peptide University does not sell peptides, supplies, or supplements. Many compounds discussed here are sold as “research chemicals” and are not approved for human use outside of clinical trials. Laws vary by country, and nothing here is a recommendation to obtain or use anything. Talk to a qualified clinician about your own situation.
Cagrilintide is an investigational long-acting amylin-receptor agonist from Novo Nordisk, in Phase 3 trials (notably combined with semaglutide as “CagriSema”). Not approved.
How it works
Amylin is a hormone co-released with insulin that promotes fullness and slows gastric emptying — a separate satiety pathway from GLP-1. Pairing an amylin analogue with a GLP-1 drug is the rationale for combining two appetite mechanisms.
The evidence
Phase 3 data for CagriSema is emerging; results have been mixed relative to sky-high expectations but still show substantial weight loss. As an investigational combination, treat any figure as provisional and read the research guide.
Safety
Side effects reported so far track the incretin class — largely gastrointestinal. Long-term human safety of amylin analogues in this context is still being established in trials.
FAQ
QWhat's CagriSema?
The investigational combination of cagrilintide + semaglutide, pairing amylin and GLP-1 mechanisms.
QIs it approved?
No — investigational, in Phase 3 at time of writing.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- Retatrutide/cagrilintide/survodutide status overview
- GLP-1 agonists for obesity: outcomes & risks (PMC)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Questions & comments
No account, no login — leave a name or stay anonymous. Ask a question, add something the article missed, or answer someone else. Be kind and cite sources where you can.